益丰药房2025年年度报告（英文版）

Yifeng Pharmacy Chain Co., Ltd. 2025 Annual Report 1/266 Company code: 603939 Company abbreviation: Yifeng Pharmacy Yifeng Pharmacy Chain Co., Ltd. 2025 Annual Report This report is prepared in both Chinese and English and is published electronically. If there is any inconsistency between the two versions, the Chinese version shall prevail. Yifeng Pharmacy Chain Co., Ltd. 2025 Annual Report 2/266 Important Notes I. The Board of Directors, directors, and senior management of the Company hereby guarantee that the contents are authentic, accurate, and complete, without false records, misleading representations or material omissions in the Annual Report, and shall take all the joint and several legal liabilities. II. All the directors have attended the meeting of the Board of Directors. III. Pan-China Certified Public Accountants LLP has issued a standard unqualified audit report for the Company. IV. Gao Yi, the Company's responsible person, Gao Youcheng, responsible person in charge of accounting work, and Guan Changfu, the accounting firm's responsible person (accounting superintendent) hereby declare and warrant that the financial report in the Annual Report is authentic, accurate, and complete. V. The plan of profit distribution or the conversion of capital reserves into share capital for the Reporting Period has been approved by the Board of Directors As audited by Pan-China Certified Public Accountants LLP (special general partnership), the undistributed profit of the Company (parent company basis) as of December 31, 2025 amounted to CN¥775,719,439.87. The Company proposes to distribute a cash dividend of CN¥0.40 (tax included) per share to all shareholders. Based on the Company’s total share capital of 1,212,392,331 shares as of March 31, 2026, the total proposed cash dividend amounts to CN¥484,956,932.40 (tax included). If the Company’s total share capital changes during the period from the date of disclosure of this profit distribution plan to the record date for the implementation of equity distribution (e.g., due to the conversion of convertible bonds), the Company intends to keep the per‑share dividend unchanged and adjust the total distribution amount accordingly. Any such adjustment will be disclosed separately. The profit distribution plan above is subject to approval by the Company’s shareholders at the general meeting before implementation. Information on uncovered tax losses of the parent company and their impact on the Company's profit distribution and other matters as of the end of the Reporting Period "□ Applicable" "√ Not applicable" VI. Risk statement on forward-looking statements "√ Applicable" "□ Not applicable" Yifeng Pharmacy Chain Co., Ltd. 2025 Annual Report 3/266 The forward-looking statements such as future plans and development strategies in the Annual Report do not constitute a substantive commitment of the Company to investors. Investors should therefore